Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
9 Cards in this Set
- Front
- Back
|
Phase non-specific agents
|
Effective at any part of cell cycle. Linear dose response curve
Cycle-specifics will kill cells actively dividing (e.g. alkylating agents) Cycle-nonspecifics kill non-cycling cells. |
|
|
Phase specific agents
|
Must be present during specific phase of cell cycle
|
|
|
Log kill hypothesis
|
Number of cell killed in constant proportion. First order process.
|
|
|
Killing mechanism
|
Sense DNA cell damage, then transduction of apoptosis pathway.
p53 - sometimes even if present, cell will repair DNA and not kill itself. upregulated with dna damage. |
|
|
Bcl-2
|
Overexpressed in follicular non-hodgkin's lymphomas. Protects against chemotherapy-induced apoptosis.
|
|
|
Targeted anti-cancer drugs
|
Not needed to be gived at maximum tolerated dose bc can get max therapeutic response without inducing serious side effects.
|
|
|
Differentiation therapy
|
e.g. using all-trans retinoic acid (ATRA) to treat acute promyelocytic leukemia (APL)
|
|
|
Increasing the MTD
|
e.g. autologous bone marrow transplant (ABMT) or autologous peripheral blood stem cell transplantation (APBSCT).
|
|
|
Development of new cancer drugs
|
Test against tumor cell lines/molecular target, test against tumor in nude mouse, then pre-clinical toxicological analysis in animal models.
then clinical testing... phase 1 - determine side effects and MTD phase 2 - In pts with many cancers, find the spectrum of activity. phase 3 - Randomize trial to see if it better than the current standard of care. |
